Literature DB >> 21122531

Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists.

Yehuda Chowers1, Andreas Sturm, Miquel Sans, Konstantinos Papadakis, Maria Gazouli, Marcus Harbord, Jörg Jahnel, Gerassimos J Mantzaris, Johannes Meier, Christian Mottet, Laurent Peyrin-Biroulet, Matthieu Allez.   

Abstract

This second section of the first ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases addresses the biological roles of TNFα and the effects and mechanisms of action of TNFα antagonists. Mechanisms underlying their failure, including induction of TNF-independent inflammatory pathways and phenomena of paradoxical inflammation are discussed.
Copyright © 2010 European Crohn's and Colitis Organisation. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21122531     DOI： 10.1016/j.crohns.2010.05.011

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


  12 in total

1.  Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Authors:  Parambir S Dulai; Brigid S Boland; Siddharth Singh; Khadija Chaudrey; Jenna L Koliani-Pace; Gursimran Kochhar; Malav P Parikh; Eugenia Shmidt; Justin Hartke; Prianka Chilukuri; Joseph Meserve; Diana Whitehead; Robert Hirten; Adam C Winters; Leah G Katta; Farhad Peerani; Neeraj Narula; Keith Sultan; Arun Swaminath; Matthew Bohm; Dana Lukin; David Hudesman; John T Chang; Jesus Rivera-Nieves; Vipul Jairath; G Y Zou; Brian G Feagan; Bo Shen; Corey A Siegel; Edward V Loftus; Sunanda Kane; Bruce E Sands; Jean-Frederic Colombel; William J Sandborn; Karen Lasch; Charlie Cao
Journal:  Gastroenterology       Date:  2018-05-30       Impact factor: 22.682

2.  Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-κB/MAPKs Pathway.

Authors:  Huatuo Zhu; Shujun Huang; Min Yue; Wenguo Chen; Chao Lu; Xinhe Lou; Chunxiao Li; Guodong Shan; Hongtan Chen; Xiaowei Xu; Guoqiang Xu; Lihua Chen
Journal:  Dig Dis Sci       Date:  2018-06-29       Impact factor: 3.199

Review 3.  Remicade® (infliximab): 20 years of contributions to science and medicine.

Authors:  Richard Melsheimer; Anja Geldhof; Isabel Apaolaza; Thomas Schaible
Journal:  Biologics       Date:  2019-07-30

4.  Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.

Authors:  Grant E Barber; Vijay Yajnik; Hamed Khalili; Cosmas Giallourakis; John Garber; Ramnik Xavier; Ashwin N Ananthakrishnan
Journal:  Am J Gastroenterol       Date:  2016-09-06       Impact factor: 10.864

5.  Development of a Machine Learning Model to Predict Non-Durable Response to Anti-TNF Therapy in Crohn's Disease Using Transcriptome Imputed from Genotypes.

Authors:  Soo Kyung Park; Yea Bean Kim; Sangsoo Kim; Chil Woo Lee; Chang Hwan Choi; Sang-Bum Kang; Tae Oh Kim; Ki Bae Bang; Jaeyoung Chun; Jae Myung Cha; Jong Pil Im; Min Suk Kim; Kwang Sung Ahn; Seon-Young Kim; Dong Il Park
Journal:  J Pers Med       Date:  2022-06-09

6.  Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways.

Authors:  Jay Luther; Manish Gala; Suraj J Patel; Maneesh Dave; Nynke Borren; Ramnik J Xavier; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2018-01-25       Impact factor: 3.199

7.  Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.

Authors:  Ayal Hirsch; Ruben J Colman; Gabriel D Lang; David T Rubin
Journal:  ACG Case Rep J       Date:  2015-07-09

Review 8.  Necroptosis in inflammatory bowel disease and other intestinal diseases.

Authors:  Sha Li; Long-Gui Ning; Xin-He Lou; Guo-Qiang Xu
Journal:  World J Clin Cases       Date:  2018-11-26       Impact factor: 1.337

9.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

Authors:  Parambir S Dulai; Siddharth Singh; Xiaoqian Jiang; Farhad Peerani; Neeraj Narula; Khadija Chaudrey; Diana Whitehead; David Hudesman; Dana Lukin; Arun Swaminath; Eugenia Shmidt; Shuang Wang; Brigid S Boland; John T Chang; Sunanda Kane; Corey A Siegel; Edward V Loftus; William J Sandborn; Bruce E Sands; Jean-Frederic Colombel
Journal:  Am J Gastroenterol       Date:  2016-06-14       Impact factor: 12.045

Review 10.  Management of Crohn's disease in poor responders to adalimumab.

Authors:  Nanne Kh de Boer; Mark Löwenberg; Frank Hoentjen
Journal:  Clin Exp Gastroenterol       Date:  2014-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.